



## Europass Curriculum Vitae

### Personal information

First name(s) / Surname(s) **Elias CASTANAS**

Address University of Crete, School of Medicine, P.O. Box 2208  
GR-71003, Heraklion (Greece)

Telephone(s) +30 2810 394580, -84, 2810 313301 Mobile | +30 6944 680204

Fax(es) +30 2810 394581

E-mail(s) castanas@med.uoc.gr; ecastana@otenet.gr

Nationality Greek, French

Date of birth 1 Jan 52

Gender Male

### Work experience

Dates **Oct 86 →**

Occupation or position held Professor of Medicine

Main activities and responsibilities Professor and Head: Laboratory of Experimental Endocrinology, University of Crete, School of Medicine

Name and address of employer University of Crete, School of Medicine  
P.O. Box 2208, 71003 Heraklion (Greece)

Type of business or sector Higher Education

Dates **Oct 89 →**

Occupation or position held Director

Main activities and responsibilities Director and Head of the Laboratory of Endocrinology-Immunology-Oncology

Name and address of employer University Hospital of Heraklion  
Voutes, 71000 Heraklion (Greece)

Type of business or sector Human Health And Social Work Activities

Dates **Oct 83 - Dec 86**

Occupation or position held Researcher

Main activities and responsibilities Researcher

Name and address of employer INSERM  
Marseille (France)

Type of business or sector Research

Dates **1980 - 1983**

Occupation or position held Assistant

Main activities and responsibilities Research and Teaching

Name and address of employer University of Marseille II, School of Medicine, Laboratory of Biochemistry  
Marseille (France)

Type of business or sector Education

Dates 1978 - 1981  
Occupation or position held Assistant  
Main activities and responsibilities Research and Treatment  
Name and address of employer Assistance Publique a Marseille, CHU  
Marseille (France)  
Type of business or sector Human Health And Social Work Activities

### Education and training

Dates 1969 - 1975  
Title of qualification awarded Diploma  
Principal subjects / occupational skills covered Medicine  
Name and type of organisation providing education and training University of Athens, School of Medicine  
Athens (Greece)

Dates 1975 - 1978  
Title of qualification awarded Doctorate in Medicine  
Name and type of organisation providing education and training University of Athens, School of Medicine  
Athens (Greece)

Dates 1978 - 1981  
Title of qualification awarded Diploma in Endocrinology-Metabolism  
Name and type of organisation providing education and training University Aix-Marseille II, School of Medicine  
Marseille (France)

Dates 1978 - 1981  
Title of qualification awarded PhD  
Principal subjects / occupational skills covered Molecular and Cellular Biology  
Name and type of organisation providing education and training University Aix-Marseille II, School of Sciences  
Marseille (France)

Dates 1981 - 1985  
Title of qualification awarded Doctorate in Sciences (DSc)  
Principal subjects / occupational skills covered Sciences  
Name and type of organisation providing education and training University Aix-Marseille II, School of Sciences  
Marseille (France)

### Personal skills and competences

Mother tongue(s) **Greek**

Other language(s)

Self-assessment  
*European level (\*)*

**English**

**French**

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user
C2	Proficient user	C2	Proficient user	C2	Proficient user	C2	Proficient user	C1	Proficient user

(\*) [Common European Framework of Reference \(CEF\) level](#)

Organisational skills and competences	Management (especially R&D)
Computer skills and competences	Proficient in the Office suite and other technical programs Programming experience
Driving licence(s)	A1, B

<b>Annexes</b>	1. Positions Held
	2. Publication Record
	3. Patents

**Annex 1**  
Positions Held

1970-1975	Research and Teaching Associate University of Athens, School of Medicine Laboratory of Biological Chemistry
1975-1978	Research and Teaching Assistant University of Athens, School of Medicine Laboratory of Biological Chemistry.
1978-1980	Assistant in Endocrinology and Metabolism, Endocrinology and Metabolism Clinic, University Aix-Marseille II.
1980-1985	University Assistant (Assistant des Sciences Fondamentales) University Aix-Marseille II Faculty of Medicine Laboratory of Biochemistry.
1985- 1997	Research Associate (Charge de Recherche INSERM) Laboratory of Experimental Neuroendocrinology, U 297, Marseille
1987-1993	Associate Professor of Experimental Medicine (Endocrinology), University of Crete, School of Medicine
1993-	Professor of Experimental Endocrinology
1989-1992	Director of the Clinical Chemistry Laboratory, University Hospital of Heraklion, Crete
1989-	Director of the Experimental Endocrinology and Immunology Department, University Hospital of Heraklion, Crete
1996-	Corresponding Member of the American Association for Cancer Research
1996-2001	Greek Representative for the European Union Action COST 825 (Mammary Gland Research)
2000-	Greek Representative for the European Union Action COST B20
1999-	<b>Different positions in DG Research EU (FP5-7):</b> <ol style="list-style-type: none"> <li>1. Evaluator of projects (FP5-FP7)</li> <li>2. Site-visitor/auditor for different projects</li> <li>3. Member of the committee for Cancer research</li> <li>4. Member of the Advisory board for FP6, Priority 1</li> <li>5. Evaluator "People" Marie-Curie actions, FP7</li> </ol>
1985-	Different positions in the Administration of the School of Medicine and the University Hospital of Heraklion, such as: <ol style="list-style-type: none"> <li>1. Head of the Department</li> <li>2. Member of the Councillors Board</li> <li>3. Vice-President of the Scientific Committee</li> </ol>
1997- 2004	Member of the Scientific Committee of the Hellenic Pasteur Institute
2010-	Director of the Hospital Department of Laboratory Medicine

## Annex 2

### Publication Record

#### a. In Peer Review Journals

1. Kaniaris P., Lekakis D., Mykoniatis M., Castanas E. Serum free-fatty acids and blood glucose levels in children under halothane, thiopentone, and ketamine anesthesia (comparative study). *Canad. Anaesth. Soc. J.* 22: 509-515, 1975
2. Kaniaris P., Katsilambros N., Castanas E., Theophanidis C. Relation between glucose tolerance and serum insulin levels in men, before and after thiopental I.V. administration. *Anesthesia Analgesia (C.R.)* 54: 718-723, 1975
3. Carayon P., Thomas-Morvan C., Castanas E., Tubiana M. Human thyroid cancer: Membrane thyrotropin binding and adenylate cyclase activity. *J. Clin. Endocrinol. Metab.* 51: 915-918, 1980
4. Conte-Devolx B., Giraud P., Castanas E., Boudouresque F., Orlando M., Gillioz P., Oliver C. Effect of neonatal treatment with monosodium glutamate on the secretion of  $\alpha$ -MSH,  $\beta$ -endorphin and ACTH in the rat. *Neuroendocrinology* 33: 207-211, 1981
5. Conte-Devolx B., Oliver C., Giraud P., Gillioz P., Castanas E., Lissitzky J.-C., Boudouresque F., Milliet Y. Effect of nicotine on the secretion of melanocorticotropin hormones in the rat. *Life Sci.* 28: 1067-1073, 1981
6. Conte-Devolx B., Oliver C., Giraud P., Castanas E., Boudouresque F., Gillioz P., Milliet Y. Adrenocorticotropin,  $\beta$ -endorphin and corticosterone secretion in Brattleboro rats. *Endocrinology* 110: 2097-2100, 1982
7. Conte-Devolx B., Oliver C., Foucault-Chiozza F., Giraud P., Castanas E., Codaccioni J.-L. Effets de la 1-desamino-8-D-arginine-vasopressine sur la fonction corticotrope de l'homme. *Nouv. Presse Med.* 11: 2566-2567, 1982
8. Giraud P., Castanas E., Conte-Devolx B., Boudouresque F., Taquet H., Orlando M., Jaquet P., Eiden L. E., Cesselin F., Gunz G., Trigano M. Enkephalins in human pheochromocytoma: Biosynthesis and secretion. *Europ. Heart J.* 3: 19-22, 1982
9. Conte-Devolx B., Rey M., Boudouresque F., Giraud P., Castanas E., Milliet Y., Codaccioni J.-L., Oliver C. Effet de l'immunisation passive avec un serum anti-CRF sur la secretion d'ACTH du rat. *C. R. Acad. Sci. (Paris)* 295: 647-650, 1982
10. Rey M., Conte-Devolx B., Grillo J.-M., Castanas E., Mersier G.-M., Boudouresque F., Giraud P., Milliet Y., Oliver C. Effet de la stimulation électrique du noyau paraventriculaire (NVP) sur la fonction corticotrope du rat Long-Evans et Brattleboro. *C. R. Acad. Sci. (Paris)* 295: 597-599, 1982
11. Giraud P., Eiden L., Castanas E., Conte-Devolx B., Boudouresque F., Jaquet P., Oliver C. Peptides opiaces de la medullosurrenale. *Nouv. Presse Med.* 11: 1867-1872, 1982
12. Giraud P., Castanas E., Patey G., Oliver C., Rossier J. Regional distribution of Methionine Enkephalin-Arg<sup>6</sup>-Phe<sup>7</sup> in the rat brain: Comparative study with the distribution of other opioid peptides. *J. Neurochem.* 41: 154-160, 1983
13. Castanas E., Giraud P., Audigier Y., Drissi R., Boudouresque F., Conte-Devolx B., Oliver C. Opiate binding sites on bovine adrenal medulla and six human pheochromocytomas. *Life Sci.* 33(1): 295-298, 1983
14. Conte-Devolx B., Rey M., Boudouresque F., Giraud P., Castanas E., Milliet Y., Codaccioni J.-L., Oliver C. Effect of 41-CRF antiserum on the secretion of ACTH,  $\beta$ -endorphin and  $\alpha$ -MSH in the rat. *Peptides* 44: 301-304, 1983
15. Boudouresque F., Trigano M., Conte-Devolx B., Giraud P., Castanas E., Gunz G., Oliver C. Formes moléculaires de l'ACTH hypophysaire et plasmatique en physiologie et pathologie. *Ann. Endocrinol.* 44: 9-14, 1983
16. Castanas E., Giraud P., Audigier Y., Drissi R., Boudouresque F., Conte-Devolx B., Oliver C. Adrenal medullary opiate receptors: Pharmacological characterization in bovine adrenal medulla and a human pheochromocytoma. *Mol. Pharmacol.* 25: 38-45, 1984

17. Castanas E., Giraud P., Drissi R., Chabrier P.-E., Conte-Devolx B., Boudouresque F., Cantau P., Cesselin F., Cupo A., Eiden L. E., Oliver C. Characterization of enkephalins and related peptides in rat hypophyseal portal blood. *Brain Res.* 310: 1-6, 1984
18. Castanas E., Giraud P., Bourhim N., Cantau P., Oliver C. Kappa 3: a novel subtype of the kappa opioid site in the bovine adrenal medulla, highly selective for Met-enkephalin-Arg<sup>6</sup>-Phe<sup>7</sup>. *Neuropeptides* 5: 133-136, 1984
19. Boudouresque F., Dutour A., Conte-Devolx B., Castanas E., Ouafik L., Codaccioni J.-L., Oliver C. Signification d'un taux eleve d'ACTH en discordance avec la clinique et le reste de la biologie. *Rev. Fr. Endocrinol.Clin.* 25: 231-235, 1984
20. Conte-Devolx B., Oliver C., Castanas E., Rey M., Guillaume V., Boudouresque F., Giraud P. La corticoliberine. *Presse Med.* 14: 737-742, 1985
21. Castanas E., Bourhim N., Giraud P., Boudouresque F., Cantau P., Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I Interaction with delta and mu sites. *J. Neurochem.* 45: 677-687, 1985
22. Castanas E., Bourhim N., Giraud P., Boudouresque F., Cantau P., Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: II Interaction with kappa sites. *J. Neurochem.* 45: 688-699, 1985
23. Bourhim N., Castanas E., Giraud P., Cantau P., Oliver C. Modification of opioid ligand binding in the central and the peripheral nervous system by different buffers. *Biochem. Biophys. Res. Commun.* 129: 328-333, 1985
24. Castanas E., Jaquet P., Gunz G., Cantau P., Giraud P. Direct action of opiates on bromocriptine-inhibited prolactin release by human prolactinoma cells in culture. *J. Clin. Endocrinol. Metab.* 61: 963-986, 1985
25. Blanc D., Cupo A., Castanas E., Bourhim N., Giraud P., Eiden L. E. Influence of acute, subchronic and chronic treatment with neuroleptics (haloperidol) on enkephalins and their precursors in the striatum of rat brain. *Neuropeptides* 5: 567-570, 1985
26. Conte-Devolx B., Grino M., Nieoullon A., Javoy-Agid F., Castanas E., Tonon M.-C., Guillaume V., Oliver C. Corticoliberine (CRF), somatostatin (SRIF), somatocrinin (GRF) and amines content in normal human hypothalamus and in patients with Parkinson's disease. *Neurosci. Letts* 56: 217-222, 1985
27. Ouafik L'H., Dutour A., Castanas E., Boudouresque F., Oliver C. Evidence for a precursor of TRH in the neonatal rat pancreas. *Biochem. Biophys. Res. Commun.* 128: 664-669, 1985
28. Dutour A., Ouafik L'H., Castanas E., Boudouresque F., Oliver C. TRH and TRH-OH in the pancreas of adult and newborn rats. *Life Sci.* 37: 177-183, 1985
29. Castanas E., Blanc D., Bourhim N., Cupo A., Cantau P., Giraud P. Reassessment of opioid binding sites in different areas of the rat brain. *Neuropeptides* 7: 369-380, 1986
30. Carydakis C., Bourhim N., Giraud P., Cantau P., Oliver C., Castanas E. Les antidepressifs tricycliques interagissent directement avec les sites de liaison opiaces dans la medullosurrenalle bovine. *C. R. Acad. Sci. (Paris)* 302: 419-422, 1986
31. Ouafik L'H., Dutour A., Salers P., Giraud P., Boudouresque F., Castanas E., Oliver C. Evidence for high peptide  $\alpha$ -amidation activity in the neonatal rat pancreas. *Biochem. Biophys. Res. Commun.* 138: 179-184, 1986
32. Nordmann J.-J., Cazalis M., Danidji G., Castanas E., Giraud P., Legros J., Louis F. Are opioid peptides co-localized with vasopressin or oxytocin? *Cell Tissue Res.* 246: 177-182, 1986
33. Giraud P., Affolter H.-U., Hotchkiss A., Castanas E., Oliver C. Eiden L. E. Regulation de la biosynthese des enkephalines dans les cellules chromaffines. *Ann. Endocrinol. (Paris)* 47: 40-42, 1986
34. Leboulenger F., Cupo A., Castanas E., Benyamin M., Pelletier G., Vaudry H. Immunohistochemical and biochemical evidence for the presence of the pentapeptide Met-enkephalin and the heptapeptide Met-enkephalin-Arg<sup>6</sup>-Phe<sup>7</sup>, but not the octopeptide Met-enkephalin-Arg<sup>6</sup>-Gly<sup>7</sup>-Leu<sup>8</sup> in amphibian chromaffin cells. *Neurochem. Int.* 8: 303-309, 1986
35. Grino M., Castanas E., Guillaume V., Boudouresque F., Conte-Devolx B., Oliver C. Binding sites for rat corticotropin releasing factor: evidence for heterogeneity and modulation by glucocorticoids. *Exp. Clin. Endocrinol.* 5: 63-68, 1986

36. Grino M., Castanas E., Conte-Devolx B., Guillaume V., Boudouresque F., Oliver C. Caracterisation et modulation des sites de liaison antehypophysaires a la corticoliberine de rat (r-CRF). *Ann. Endocrinol. (Paris)* 47: 51-53, 1986
  37. Ouafik L'H., Dutour A., Giraud P., Boudouresque F., Castanas E., Oliver C. Mise en evidence d'un precurseur pour la TRH dans le pancreas du rat nouveau-ne. *Ann. Endocrinol. (Paris)* 47: 43-44, 1986
  38. Ouafik L'H., Giraud P., Salers P., Dutour A., Castanas E., Boudouresque F., Oliver C. Evidence for high peptide  $\gamma$ -amidation activity iná the pancreas from neonatal rats. *Proc. Natl. Acad. Sci. (USA)* 84: 261-264, 1987
  39. Cantau P., Bourhim N., Giraud P., Oliver C., Castanas E. Photoaffinity crosslinking of etorphine with opioid binding sites in the bovine adrenal medulla. *Biotechnol. Appl. Biochem.* 9: 114-122, 1987
  40. Grino M., Guillaume V., Castanas E., Boudouresque F., Conte-Devolx B., Oliver C. Effect of passive immunization against corticotropin releasing factor (CRF) on the postadrenalectomy changes of CRF binding sites in the rat anterior pituitary gland. *Exp. Clin. Endocrinol.* 5: 63-68, 1987
  41. Karydakís P., Papastratis G., Alexiou D., Castanas E., Skalkeas G. Le role de l'AMP cyclique dans la secretion gastrique: Mecanisme d'action de la pentagastrine et de la cimetidine. *J. Chir. (Paris)* 125: 484-490, 1988
  42. Hatzoglou A., Prekezes J., Tsami M., Castanas E. (1992) Protein measurement of particulate and solubilized ovine liver membranes. *Ann. Clin. Biochem.* 29 659-662, 1992
  43. Bourhim N., Castanas E., Giraud P., Oliver C. Differential modulation of solubilized opioid binding sites by cations in the bovine adrenal medulla. *Mol. Neuropharmacol.* 3, 139-146, 1993
  44. Bourhim N., Cantau Ph., Giraud P., Castanas E. Comparative thermodynamics of opioid receptor-ligand interaction in the bovine adrenal medulla membranes: Evidence of opioid site heterogeneity. *Compar. Biochem. Physiol.* 104B, 607-615, 1993
  45. Hatzoglou A., Romain S., Dalapascha H., Castanas E. Acidification reveals a greater number of Epidermal Growth Factor Receptors in human membrane preparations. *Cli. Chim. Acta* 227, 97-109, 1994
  46. Krambovitis E., Hatzidakis G., Hatzoglou A., Romain S., Durand A., Stefanakis A., Castanas E. An enzyme-ligand immunoassay for simultaneous quantitation of estrogen and progesterone receptors in breast cancer microsamples. *Clin. Chem.* 41, 48-53, 1995
- Hatzoglou A., Gravanis A., Zoumakis E., Margioris A., Castanas E. Identification and characterization of opioid binding sites present in the Ishikawa human endometrial adenocarcinoma cell line. *J. Clin. Endocrinol. Metab.* 80, 418-423, 1995
47. Papavasiliou S., Brue Th., Jaquet Ph. Castanas E. Non Linear Analysis of the Dynamics of Prolactin diurnal secretion in man: Findings, conclusions aid implications. *Neuroendocrinol.* 62, 444-453, 1995
  48. Hatzoglou A., Ouafik L'H., Bakogeorgou E., Thermos K., Castanas E. Morphine cross-reracts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line, and decreases cell proliferation. *Cancer Res.* 55, 5632-5636, 1995
  49. Hatzoglou A., Bakogeorgou E. Castanas E. The antiproliferative effect of opioid agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. *Eur. J. Pharmacol.* 296, 199-207, 1996
  50. Hatzoglou A., Bakogeorgou E., Hatzoglou Ch., Martin P.M., Castanas E. Antiproliferative and Receptor binding properties of  $\alpha$ - and  $\beta$ - casomorphin peptides, in the T47D human breast cancer cell line. *Europ. J. Pharmacol.* 310, 217-223, 1996
  51. Hatzoglou A., Margioris A., Bakogeorgou E., Gravanis A., Castanas E. Identification, Characterization and localisation of Corticotropin-Releasing Hormone Receptors in Human Placenta. *Life Sci.* 59, 1871-1879, 1996
  52. Hatzoglou A., Bakogeorgou E., Stournaras C., Emmanuel D., Castanas E. Identification and characterisation of opioid and somatostatin binding sites in the Kidney Oposum (OK) cell line, and their effect on growth. *J. Cell. Biochem.* 63, 410-421, 1996
  53. Kampa M., Loukas S., Hatzoglou A., Martin P., Martin P-M., Castanas E. Identification of a novel opioid peptide derived from alpha-S1 human casein (alpha-S1 casomorphin, and alpha-S1 casomorphin-amide) *Biochem. J.* 319, 903-908, 1996
  54. Bakogeorgou E., Hatzoglou A., Castanas E. Taxol interacts with opioid binding sites in the T47D human breast cancer cell line. *Biochem. Biophys. Res. Commun.* 235, 201-204, 1997

55. Kampa M., Bakogeorgou E., Hatzoglou A., Damianaki A., Martin P-M., Castanas E. Opioid alkaloids and casomorphin peptides decrease prostatic cancer cell line (LNCap, PC3 and DU145) proliferation through a partial interaction with opioid receptors. *Eur. J. Pharmacol.* 335, 255-266, 1997
56. Alexandrakis M., Coulocheri S., Kyriakou D., Bouros D., Xirouhaki N., Siafakas N., Castanas E., Eliopoulos G. Diagnostic value of ferritin, haptoglobin,  $\alpha$ 1-antitrypsin, lactate dehydrogenase and complement factors C3 and C4 in pleural effusion differentiation. *Respir. Med.* 91, 517-523, 1997
57. Petinaki E., Nikolopoulos S., Castanas E. Low stimulation of peripheral lymphocytes, following in vitro application of Emdogain. *J. Clin. Periodontol.* 25, 715-20, 1998
58. Papakonstanti E.A., Bakogeorgou E., Castanas E., Emmanouel D.S., Hartig R., Stournaras C. Early alterations of actin cytoskeleton in OK cells by opioids. *J. Cell. Biochem.* 70, 60-69, 1998
59. Panagiotou S., Hatzoglou A., Calvo F., Matrín P-M., Castanas E. Modulation of the estrogen-regulated proteins cathepsin D and pS2 in hormone-sensitive breast cancer cell lines (MCF7 and T47D) by opioid agonists: Evidence for an interaction between the two systems. *J. Cell. Biochem.* 71, 416-428, 1998
60. Kampa M., Margioris A.N., Hatzoglou A., Dermizaki E., Gravanis A., Henry J-F., Oliver C., Castanas E. Kappa1 are the dominant opioid binding sites in surgical specimens of human pheochromocytomas and a human pheochromocytoma (KAT45) cell line. *Europ. J. Pharmacol.* 364, 255-262, 1999
61. Panagiotou S., Bakogeorgou E., Papakonstanti E., Hatzoglou A., Wallet F., Dussert C., Stournaras C., Martin P-M., Castanas E. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: Involvement of cytoskeletal elements. *J. Cell. Biochem.* 73, 204-211, 1999
62. Damianaki A., Bakogeorgou E., Kampa M., Notas G. Hatzoglou A., Panagiotou S., Gemetzi C., Kouroumalis E., Martin P-M., Castanas E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. *J. Cell. Biochem.* 78, 429-441, 2000
63. Kampa M., Hatzoglou A., Notas G., Damianaki A., Bakogeorgou E., Gemetzi, C., Kouroumalis E., Martin P-M., Castanas E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. *Nutr. Cancer* 37, 223-233, 2000
64. Chatzaki E., Margioris A., Makrigiannakis A., Castanas E., Georgoulis V., Gravanis A. Kappa opioids and transforming growth factor beta1 interact in human endometrial cells. *Mol. Human Reprod.* 6, 610-617, 2000
65. Nikolopoulos S., Naoumidou I., Manousaki A., Theodorides D., Helidonis E., Castanas E. Safety of ArF-excimer laser for the removal of dental plaque and calculi: An ex-vivo histological study. *J. Clin. Laser Med. Surg.* 18, 295-300, 2000
66. Hatzoglou A., Bakogeorgou E., Kampa M., Panagiotou S., Martin P-M., Loukas S., Castanas E. Somatostatin and Opioid Receptors in mammary tissue: Role in cancer cell growth. *Adv. Exper. Med. Biol.* 480, 55-63, 2000
67. Kampa M., Hatzoglou A., Notas G., Niniraki M., Kouroumalis E., Castanas E. Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. *Cell Death Differ.* 8, 943-952, 2001
68. Koutroubakis J.E., Petinaki E., Mouzas I.A., Vlachonikolis I.G., Anagnostopoulou E., Maniatis A.N., Castanas E., Kouroumalis E.A. Anti-saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. *Am. J. Gastroenterol.* 96, 449-454, 2001
69. Kampa M., Loukas S., Hatzoglou A., Tsapis A., Castanas E. Receptorphin: A new opioid peptide with kappa receptor affinity and potent antiproliferative action, derived from the sequence of the opioid receptor. *BMC Pharmacology*, 1, 9(1), 2001
70. Kampa M., Papakonstanti E.A., Hatzoglou A., Stathopoulos E.N., Stournaras C., Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton. *FASEB J.* 16, 1429-1431, 2002
71. Hatzoglou A., Deshayes F., Madry C., Lapree G., Castanas E., Tsapis A. Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. *BMC Mol. Biol* 3 (1), 4, 2002
72. Nikolopoulos S., Petinaki E., Castanas E. Immunological Effects of Emdogain® in Humans: One year results. *Int. J. Periodont. Restor. Dent.* 22, 269-278, 2002



73. Koulentaki M, Valetas V, Xidakis K, Kouroumalis A, Petinaki E, Castanas E, Kouroumalis E. Matrix metalloproteinases and their inhibitors in acute viral hepatitis. *J Viral Hepat.* 9, 189-93, 2002
74. Hatzoglou H, Hatzoglou A, Gourgoulisian K, Castanas E, Molyvdas P. Rapid effects of the 17 $\beta$ -estradiol and progesterone in sheep pleura via a nitric oxide pathway. *J Appl. Physiol.* 93, 752-758, 2002
75. Kampa M., Nistikaki A., Tsaousis V, Maliaraki N., Notas G., Castanas E. A new automated method for the determination of the Total Antioxidant Capacity (TAC) of human plasma, based on the crocin bleaching assay. *BMC Chemical Pathology* 2: 3, 2002
76. Stathopoulos E.N., Dambaki C., Kampa M., Theodoropoulos P.A., Anezinis P., Delakas D., Delides G.S., Castanas E. Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. *BMC, Clinical Pathology* 3,1, 2003
77. Papakonstanti E.A., Kampa M., Castanas E., Stournaras C. A rapid, non-genomic, signaling pathway regulates the actin reorganization induced by membrane testosterone receptors' activation. *Mol. Endocrinology* 17, 870-881, 2003
78. Kallergi G, Tsapara A., Kampa M., Krasagakis K., Castanas E., Stournaras C. Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and non-malignant MCF12A human breast epithelial cells. *Exp. Cell Res* 288, 94-109, 2003
79. Malliaraki N., Mpliamplias D., Kampa M., Margioris A.N., Castanas E. Total and Corrected Antioxidant Capacity in patients undergoing hemodialysis. *BMC Nephrology* 4:4, 2003
80. Ganotakis E.s., Mandalaki K., Tampakaki M., Malliaraki N., Mandalakis E., Vrentzos G., Melissas J., Castanas E. Subclinical hypothyroidism and Lipid abnormalities in older women attending a vascular disease prevention clinic: Effect of thyroid replacement therapy. *Angiology* 54: 569-576, 2003
81. Kampa M., Alexaki VI., Notas G., Nifli AF., Nistikaki A., Hatzoglou A., Bakogeorgou E., Kouimtoglou E., Blekas G., Boskou D., Gravanis A., Castanas E. Antiproliferative and apoptotic effects of selective Phenolic acids on T47D human breast cancer cells: Potential mechanisms of action. *Breast Cancer Res.* 6: R63-R74, 2004
82. Alexandrakis MG., Passam FH., Kyriakou DS., Christophoridou AV., Perisinakis K., Hatzivasili A., Foudoulakis A., Castanas E. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. *Am J Hematol.* 75: 101-106, 2004
83. Dermitzaki E, Tsatsanis C, Alexaki I, Castanas E, Margioris AN. Roles of Protein Kinase A (PKA) and PKC on Corticotropin-Releasing Hormone (CRH)-Induced Elevation of Cytosolic Calcium from Extra- and Intra-cellular Sources. *Hormones*, 3, 252-258, 2004
84. Kampa M., Papakonstanti E., Hatzoglou A., Stournaras C., Castanas E. Opioids revert the rapid, non-genomic, effects of membrane testosterone receptors in the human prostate LNCaP cell line. *Exp. Cell. Res.* 294, 434-445, 2004
85. Koulentaki M., Notas G., Petinaki E., Valetas V., Mouzas I.A., Castanas E., Kouroumalis E. A. Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. *Eur J Intern Med.* 15, 35-38, 2004
86. Charalampopoulos I., Tsatsanis C., Dermitzaki I., Alexaki V.I., Castanas E., Margioris A.N., Gravanis A. Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medullary cells against apoptosis, via anti-apoptotic Bcl-2 proteins. *Proc. Natl. Acad. Sci (USA)* 101, 8209-14, 2004
87. Koutroubakis I.E., Malliaraki N., Dimoulis P., Karmiris K., Castanas E., Kouroumalis E. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. *Dig. Dis. Sci.* 49, 1433-1437, 2004
88. Alexaki VI., Charalampopoulos I., Kampa M., Vassalou H., Theodoropoulos P., Hatzoglou A., Gravanis A., Castanas E. Estrogen exert neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. *FASEB J.* 18, 1594-1596, 2004
89. Nikolopoulos S., Naoumidou I., Nikolopoulou M. Helidonis E., Castanas E. ArF-193 Excimer Laser and Emdogain® in the Treatment of Experimental Periodontitis: An Experimental Study in Rabbits. *Photomedicine Laser Surg* 22, 357-362, 2004

90. Dermitzaki I, Tsatsanis C, Alexaki VI, Castanas E, Margioris AN. Roles of protein kinase A (PKA) and PKC on corticotropin-releasing hormone (CRH)-induced elevation of cytosolic calcium from extra- and intra-cellular sources. *Hormones (Athens)* 3, 252-258, 2004
91. Hatzoglou A, Kampa M., Castanas E. Opioid-somatostatin interactions in regulating cancer cell growth. *Front. Biosci.* 10, 244-256, 2005
92. Notas G., Kolios G., Mastrodimitou N., Kampa M., Vasilaki A., Xidakis C., Castanas E., Thermos K., Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of Somatostatin receptors. *J. Hepatol* 40, 792-798, 2005
93. Papageorgiou M, Stiakaki E, Malliaraki N, Dimitriou H, Notas G, Castanas E, Kalmanti M. Decreased plasma total antioxidant capacity in children under cancer chemotherapy. *Leukemia Res.* 29, 11-16, 2005
94. Dermitzaki E., Tsatsanis C., Charalampopoulos I., Androurlidaki A., Alexaki VI., Castanas E., Gravanis A., Margioris AN. Corticotropin-Releasing Hormone Activates Protein Kinase C in an isoenzyme-specific manner. *Biochem. Biophys. Res. Commun.* 327, 828-836, 2005
95. Notas G., Maliaraki N., Kampa M., Dimoulios F., Matrella E., Castanas E., Kouroumalis E. Patients with primary biliary cirrhosis have increased serum total antioxidant capacity measured with the crocin bleaching assay. *World J. Gastroenterol.* 11, 4194-4198, 2005
96. Hatzoglou A, Kampa M., Kogia C., Charalampopoulos I., Theodoropoulos PA., Anezinis P., Dambaki C., Papakonstanti EA, Stathopoulos EN., Stournaras C., Gravanis A., Castanas E. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. *J. Clin. Endocrinol. Metab.* 90, 893-903, 2005
97. Kampa M., Nifli AP, Charalampopoulos I., Alexaki VI., Theodoropoulos PA., Stathopoulos EN., Gravanis A., Castanas E. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. *Exp. Cell Res.* 307, 41-51, 2005
98. Nifli AP., Kampa M., Alexaki VI., Notas G., Castanas E. Polyphenol interaction with the T47D human breast cancer cell line. *J. Dairy Res* 72, S1, 44-50, 2005
99. Dambaki C., Kogia Ch., Kampa M., Theodoropoulos P., Anezinis P., Castanas E., Stathopoulos EN. Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections. *BMC Cancer* 5, 148, 2005
100. Nifli AP, Bosson-Kouamé A., Papadopoulou N, Kogia C, Kampa M, Castagnino C, Stournaras C, Vercauteren J, Castanas E. Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. *Exp. Cell Research* 309, 329-339, 2005
101. Roussakis E., Liepouri F., Nifli AP., Castanas E., Deligeorgiev TG., Katerinopoulos HE. ICPBC and C12-ICPBC: Two new red emitting, fluorescent Ca<sup>2+</sup> indicators excited with visible light. *Cell Calcium* 39, 3-11, 2006
102. Nikolopoulos S., Karetso A., Nikolopoulou K., Karoutis A., Helidonis E., Castanas E. ArF 193 excimer laser: a method to conserve ancient teeth and bones with minimal damage. *Studies in Conservation* 2006
103. Alexaki VI., Charalampopoulos I., Kampa M., Nifli AP., Hatzoglou A., Gravanis A., Castanas E. Activation of membrane estrogen receptors induce pro-survival kinases. *J Steroid Biochem Mol Biol* 98, 97-110, 2006
104. Sharifabrizi A, Nifli AP, Ansari M, Saadat F, Reza Ebrahimkhani H, Alizadeh N, Nasseh A, Alexaki VI, Reza Dehpour A, Castanas E, Reza Khoramizadeh M. MMP-2 secretion in WEHI 164 fibrosarcoma cells is NO-related and modified by morphine. *Eur. J. Pharmacol* 530, 33-39, 2006
105. Kampa M., Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. *Mol. Cell. Endocrinol.* 246, 76-82, 2006
106. Charalampopoulos I., Alexaki V-I., Lazaridis I., Dermitzaki R., Avlonitis N., Tsatsanis C., Kalogeropoulou T., Margioris AN., Castanas E., Gravanis A. G-protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone (DHEA). *FASEB* 20, 577-579, 2006
107. Nifli AP., Notas G, Mamoulaki M, Niniraki M., Ampatzaki V., Theodoropoulos PA., Kopnitsky MJ, Castanas E. Comparison of multiplex, ELISA and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum. *J Immunol Methods* 311, 189-197, 2006

108. Melissas J, Malliaraki N, Papadakis JA, Taflampas P, Kampa M, Castanas E. Plasma antioxidant capacity in morbidly obese patients before and after weight loss. *Obesity Surg* 16, 314-320, 2006
109. Kampa M, Kogja C, Theodoropoulos PA, Anezinis P, Charalampopoulos I, Papakonstanti EA, Stathopoulos EN, Hatzoglou A, Stournaras C, Gravanis A, Castanas E. Activation of membrane androgen receptors potentiates the antiproliferative effects of Taxol on human prostate cancer cells. *Mol Cancer Therap* 5, 1342-1351, 2006
110. Alexaki V-I, Dermitzaki R., Charalampopoulos I., Kampa M., Nifli AP., Gravanis A., Margioris AN., Castanas E. Neuronal differentiation of PC12 cells abolishes the expression of membrane androgen receptors. *Exp Cell Res* 312, 2745-2756, 2006
111. Tsiakalou V, Polioudaki H, Nifli AP, Koulentaki M, Akoumianaki T, Kouroumalis E, Castanas E, Theodoropoulos PA. Optimization of the immunofluorescence screening for the detection of anti nuclear envelope antibodies in PBC. *BMC Immunology* 7, 20, 2006
112. Notas G., Nifli A-P., Kampa M., Vercauteren J., Kouroumalis E., Castanas E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells by inducing cell cycle arrest and NOS activation. *BBA\_Gen. Subj* 1760, 1657-1666, 2006
113. Dimitriou H, Bakogeorgou E, Kampa M, Notas G, Stiakaki E, Kouroumalis E, Kalmanti M, Castanas E. Kappa-opioids induce a reversible inhibition of CFU-GM from CD133+ cord blood cells. *Cytotherapy* 8, 367-374, 2006
114. Charalampopoulos I, Alexaki VI, Tsatsanis C, Minas V, Dermitzaki E, Lasaridis I, Vardouli L, Stournaras C, Margioris AN, Castanas E, Gravanis A. Neurosteroids, as endogenous inhibitors of neuronal cell apoptosis in aging. *Ann N Y Acad Sci* 1088, 139-152, 2006
115. Kochiadakis GE, Marketou ME, Arfanakis DA, Sfiridaki K, Skalidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE. Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. *Atherosclerosis* 194, 433-8, 2007
116. Nifli A-P, Theodoropoulos PA, Munier S, Castagnino C, Roussakis E, Katerinopoulos HE, Vercauteren J, Castanas E. Quercetin exhibits a specific fluorescence in cellular milieu: a valuable tool for the study of its intracellular distribution. *J Agric Food Chem* 55, 2873-2878, 2007
117. Kampa M, Nifli AP, Notas G, Castanas E. Polyphenols and cancer cell growth. *Rev Physiol Biochem Pharmacol*, 159, 79-113, 2007
118. Notas G, Kampa M, Nifli AP, Xidakis K, Papasava D, Thermos K, Kouroumalis E, Castanas E. The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors. *Eur J Pharmacol* 555, 1-7, 2007
119. Kampa M, Castanas E. Health effects of air pollution. *Env. Pollut.* 151, 362-367, 2008
120. Pelekanou V, Kampa M, Kafousi M, Dambaki K, Darivianaki K, Sanidas E, Tsiftsis DD, Stathopoulos EN, Castanas E. Erythropoietin and its receptor in breast cancer: Correlation with steroid receptors and outcome. *Cancer Epidemiol Biomarker Prev*, 19, 2019-2023, 2007
121. Litos IK, Emmanouilidou E, Glynou KM, Laios E, Ioannou PC, Christopoulos TK, Kampa M, Castanas E, Gravanis A. Rapid genotyping of CYP2D6, CYP2C19 and TPMT polymorphisms by primer extension reaction in a dipstick format. *Anal Bioanal Chem.* 389, 1849-1857, 2007
122. Vassou D., Bakogeorgou E., Kampa M., Dimitriou H., Hatzoglou A., Castanas E. Opioids modulate constitutive B-lymphocyte secretion. *Int. Immunopharmacol.* 8, 633-644, 2008
123. Kampa M., Pelekanou V., Castanas E. Membrane-initiated steroid action in breast and prostate cancer. *Steroids* 73, 953-960, 2008
124. Vassou D., Kampa M., Hatzoglou A., Castanas E. Opioids modulate cancer cell migration in a cell-specific manner: Implication of bradykinin B2 receptor. *J. Cell. Mol. Med.* (in press), 2008
125. Pelekanou V., Kampa M., Kafousi M., Darivianaki K., Sanidas E., Tsiftsis DD., Stathopoulos EN., Tsapis A., Castanas E. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. *BMC Cancer*, 8:76, 2008

126. Alexaki VI., Charalampopoulos I., Panayotopoulou M., Kampa M., Gravanis A., Castanas E. Dehydroepiandrosterone protects human keratinocytes against apoptosis through membrane binding sites. *Exp. Cell Res.* 315, 2275-2283, 2009
127. Alexaki VI., Notas G., Pelekanou V., Kazmpa M., Valkanou M., Theodoropoulos P., Stathopoulos EN., Tsapis A., Castanas E. Adipocytes as immune cells: differential expression of TWEAK, BAFF and APRIL and their receptors (Fn14, BAFF-R, TACI and BCMA) at different stages of normal and pathological adipose tissue development. *J. Immunol.* 183, 5948-5956, 2009
128. Notas G., Pelekanou V., Castanas E., Kampa M. Conjugated and non-conjugated androgen differentially modulate specific early gene transcription in breast cancer in a cell-specific manner. *Steroids*, 75, 611-618, 2010.
129. Pelekanou V, Notas G, Sanidas E, Tsapis A, Castanas E, Kampa M. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. *Mol. Oncol.* 4, 135-149, 2010.
130. Tsangaridou E, Polioudaki H, Sfakianaki R, Samiotaki M, Tzardi M, Koulentaki M, Panayotou G, Kouroumalis E, Castanas E, Theodoropoulos PA. Differential detection of nuclear envelope autoantibodies in primary biliary cirrhosis using routine and alternative methods. *BMC Gastroenterol.* 10, 28, 2010
131. Lionis C, Anyfantakis D, Symvoulakis EK, Shea S, Panagiotakos D, Castanas E. Bio-psychosocial determinants of cardiovascular disease in a rural population on Crete, Greece: formulating a hypothesis and designing the SPILI-III study. *BMC Research Notes* 2010, 3:258.
132. Sfakianaki O, Koulentaki M, Tzardi M, Tsangaridou E, Theodoropoulos PA, Castanas E, Kouroumalis EA. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. *World J Gastroenterol.* 16, 4938-43, 2010.
133. Pelekanou V, Kampa M, Gallo D, Notas G, Troullinaki M, Du villier H, Jacquot Y, Stathopoulos EN, Castanas E, Leclercq G. The estrogen receptor alpha-derived peptide ER $\alpha$ 17p (P(295)-T(311)) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ER $\alpha$  status. *Mol Oncol.* 5, 36-47, 2011.
134. Kampa M, Theodoropoulou K, Mavromati F, Pelekanou V, Notas G, Lagoudaki ED, Nifli AP, Morel-Salmi C, Stathopoulos EN, Vercauteren J, Castanas E. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer. *J Pharmacol Exp Ther.*, 337, 24-32, 2011
135. Pelekanou V, Notas G, Theodoropoulou K, Kampa M, Takos D, Alexaki VI, Radojicic J, Sofras F, Tsapis A, Stathopoulos EN, Castanas E. Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. *Anal Cell Pathol:Cell Oncol* 34, 49-60, 2011
136. Vassou D, Notas G, Hatzoglou A, Castanas E, Kampa M. Opioids increase bladder cancer cell migration via bradykinin B2 receptors. *Int J Oncol* 39, 697-707, 2011.
137. Karakosta P, Chatzi L, Plana E, Margioris A, Castanas E, Kogevinas M. Leptin levels in cord blood and anthropometric measures at birth: a systematic review and meta-analysis. *Paediatr Perinat Epidemiol.* 25, 150-63, 2011.
138. Lazaridis I, Charalampopoulos I, Alexaki I, Avlonitis N, Padiaditakis I, Efstathopoulos P, Calogeropoulou T, Castanas E, Gravanis A. Neurosteroid dehydroepiandrosterone interacts with Nerve Growth Factor (NGF) receptors, preventing neuronal apoptosis. *PLOS Biol.* 9(4):e1001051, 2011
139. Kampa M, Pelekanou V, Gallo D, Notas G, Troullinaki M, Padiaditakis I, Charalampopoulos I, Jacquot Y, Leclercq G, Castanas E. ER $\alpha$ 17p, an ER $\alpha$  P(295) -T(311) fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements. *J Cell Biochem.* 112, 3786-96, 2011.
140. Notas G, Nifli AP, Kampa M, Pelekanou V, Theodoropoulos P, Vercauteren J, Castanas E. Quercetin is transported into cells, accumulates in nuclear structures and triggers specific gene expression in epithelial cells. *J Nutr Biochem* 23, 356-666, 2012
141. Notas G, Kampa M, Pelekanou V, Castanas E. Interplay of estrogen receptors and GPR30 for the regulation of early membrane-initiated transcriptional effects: A pharmacological approach. *Steroids*, 97, 243-250, 2012
142. Alexaki VI, Simantiraki D, Panayiotopoulou M, Rasouli O, Venihaki M, Castana O, Alexakis D, Kampa M, Stathopoulos EN, Castanas E. Adipose tissue-derived mesenchymal cells support skin re-epithelialization through secretion of KGF-1 and PDGF-BB: comparison with dermal fibroblasts. *Cell Transplantation* 2012, (in press)
143. Pelekanou V, Notas G, Kampa M, Tsenteliero E, Radojicic J, Leclercq G, Castanas E, Stathopoulos EN. ER $\alpha$ 36, a new variant of the ER $\alpha$  is expressed in triple-negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. *Steroids* 77, 928-934, 2012

144. Karakosta P, Chatzi L, Bagkeris E, Daraki V, Alegakis D, Castanas E, Kogevinas M, Kampa M. First- and Second-Trimester Reference Intervals for Thyroid Hormones during Pregnancy in "Rhea" Mother-Child Cohort, Crete, Greece *J Thyroid Res* 2011;490783490783, 2011
145. Alexaki VI, Pelekanou V, Notas G, Venihaki M, Kampa M, Dessirier V, Sabour-Alaoui S, Stathopoulos EN, Tsapis A, Castanas E. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies. *Endocrinology* 153, 739-749, 2012
146. Kampa M, Notas G, Pelekanou V, Troullinaki M, Andrianaki M, Azariadis K, Kampouri E, Lavredaki K, Castanas E. Early membrane-initiated transcriptional effects of estrogen in breast cancer cells: First pharmacological evidence for a novel membrane estrogen receptor element (ERx). *Steroids* 77, 959-967, 2012
147. Byrne C, Khemtémourian L, Pelekanou V, Kampa M, Leclercq G, Sagan S, Castanas E, Burlina F, Jacquot Y. ER $\alpha$ 17p, a peptide reproducing the hinge region of the estrogen receptor  $\alpha$  associates to biological membranes: A biophysical approach. *Steroids* 77, 979-987, 2012
148. Sabour Alaoui S, Dessirier V, de Araujo E, Alexaki VI, Pelekanou V, Lkhider M, Stathopoulos EN, Castanas E, Bagot M, Bensussan A, Tsapis A. TWEAK Affects Keratinocyte G2/M Growth Arrest and Induces Apoptosis through the Translocation of the AIF Protein to the Nucleus. *PLOS One* 7(3):e33609, 2012
149. Kampa M, Castanas E. The Seventh International Meeting on Rapid Responses to Steroid Hormones, RRSB 2011 (Editorial). *Steroids* 77, 891, 2012
150. Karakosta P, Georgiou V, Fthenou E, Margioris A, Castanas E, Kogevinas M, Kampa M, Chatzi L. Gender-specific reference intervals for cord blood leptin in Crete, Greece. *Eur. J. Pediatr.* 171, 1563-1566, 2012
151. Karakosta P, Alegakis D, Georgiou V, Roumeliotaki T, Fthenou E, Vassilaki M, Boumpas D, Castanas E, Kogevinas M, Chatzi L. Thyroid Dysfunction and Autoantibodies in Early Pregnancy Are Associated with Increased Risk of Gestational Diabetes and Adverse Birth Outcomes. *J. Clin. Endocrinol. Metab.* 97: 4464-4472, 2012
152. Notas G, Alexaki VI, Kampa M, Pelekanou V, Charalampopoulos I, Sabour-Alaoui S, Padiaditakis I, Dessirier V, Gravanis A, Stathopoulos EN, Tsapis A, Castanas E. APRIL Binding to BCMA Activates a JNK2-FOXO3-GADD45 Pathway and Induces a G2/M Cell Growth Arrest in Liver Cells. *J Immunol.* 189, 4748-4758, 2012
153. Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J, Mavroudis D, Castanas E, Stathopoulos EN. Immunohistochemical study of pElk-1 expression in human breast cancer: Association with breast cancer biologic profile and clinicopathologic features. *Breast.* 22, 89-952, 2013
154. Notas G, Kampa M, Pelekanou V, Troullinaki M, Jacquot Y, Leclercq G, Castanas E. Whole transcriptome analysis of the ER $\alpha$  synthetic fragment P295-T311 (ER $\alpha$ 17p) identifies specific ER $\alpha$ -isoform (ER $\alpha$ , ER $\alpha$ 36)-dependent and -independent actions in breast cancer cells. *Mol Oncol.* 7, 595-610, 2013
155. Kampa M, Pelekanou V, Notas G, Stathopoulos EN, Castanas E. The estrogen receptor: two or more molecules, multiple variants, diverse localizations, signaling and functions. Are we undergoing a paradigm-shift as regards their significance in breast cancer? *Hormones (Athens)* 12, 69-85, 2013
156. Pelekanou V, Notas G, Stathopoulos EN, Castanas E, Kampa M. Androgen receptors in early and castration resistant prostate cancer: friend or foe? *Hormones (Athens)* 12, 224-235, 2013
157. Byrne C, Miclet E, Broutin I, Gallo D, Pelekanou V, Kampa M, Castanas E, Leclercq G, Jacquot Y. Identification of Polyproline II Regions Derived From the Proline-Rich Nuclear Receptor Coactivators PNRC and PNRC2: New Insights for ER $\alpha$  Coactivator Interactions. *Chirality* 25, 628-642, 2013
158. Karakosta P, Georgiou V, Fthenou E, Papadopoulou E, Roumeliotaki T, Margioris A, Castanas E, Kampa M, Kogevinas M, Chatzi L. Maternal weight status, cord blood leptin and fetal growth: a prospective mother-child cohort study (rhea study). *Paediatr Perinat Epidemiol.* 27: 461-471, 2013
159. Anyfantakis D, Symvoulakis EK, Panagiotakos DB, Tsetis D, Castanas E, Shea S, Venihaki M, Lionis C. Impact of religiosity/spirituality on biological and preclinical markers related to cardiovascular disease. Results from the SPIII III study. *Hormones (Athens)* 12, 386-396, 2013
160. Pelekanou V, Notas G, Kampa M, Tsentlierou E, Stathopoulos EN, Tsapis A, Castanas E. BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 Proteins Are Related to Human Glioma Tumor Grade: Immunohistochemistry and Public Microarray Data Meta-Analysis. *PLOS One* 8, e83250, 2013

161. Koundourakis NE, Androulakis N, Spyridaki EC, Castanas E, Malliaraki N, Tsatsanis C, Margioris AN. Effect of different seasonal strength training protocols on circulating androgen levels and performance parameters in professional soccer players. *Hormones (Athens)*. 13, 104-118, 2014
162. Notas G, Bariotakis M, Kalogrias V, Andrianaki M, Azariadis K, Kampouri E, Theodoropoulou K, Lavrentaki K, Kastrinakis S, Kampa M, Agouridakis P, Pirintsos S, Castanas E. Accurate Prediction of Severe Allergic Reactions by a Small Set of Environmental Parameters (NDVI, Temperature). *PLoS One*. e0121475, 2015
163. Duijker G, Bertias A, Symvoulakis EK, Moschandreas J, Malliaraki N, Derdas SP, Tsikalas GK, Katerinopoulos HE, Pirintsos SA, Sourvinos G, Castanas E, Lionis C. Reporting effectiveness of an extract of three traditional Cretan herbs on upper respiratory tract infection: results from a double-blind randomized controlled trial. *J Ethnopharmacol*. 163, 157-166, 2015

**b. In non-peer Review Journals, and Congress Proceedings**

1. Kaniaris P., Hambouri O., Tsoumplekou E., Castanas E. Relation between ethrane and renal function. *Arch. Med. Soc. (Greece)* 2: 425-428, 1977
2. Castanas E., Livanou Th., Oikonomidou I, Sofroniadou K. Enzymatic determination of GTP and LDH in thalasemia. *Arch. Med. Soc. (Greece)* 2: 215-218, 1977
3. Giraud P., Castanas E., Oliver C., Eiden L. E., Boudouresque F., Jaquet P., Conte-Devolx B., Cesselin F. Mise en evidence d'enkephalines dans les pheochromocytomes. *Arch. Mal. Coeur (suppl)* 143-146, 1982
4. Castanas E., Hatzoglou A. Biological factors with diagnostic or prognostic value in breast cancer. *Iatriki*, 66, 264-276, 1993
5. Papavasiliou S., Castanas E., Kalmanti M. Leydig cell function in boys with testicular relapse of acute lymphocytic leukemia. *Il Friuli Medico-Alpe Adria J. Med.* 48: 43-47, 1993
6. Hatzoglou A., Prekezes I., Castanas E. Protein assay in membrane preparations: Comparison of different methods. *Arch. VI Congress of the Cretan Medical Society*) 414-416, 1993
7. Hatzoglou A., Romain S., Martin P-M., Vlachonikolis J., Castanas E. Biological parameters of primary and metastatic breast cancer. *Arch. VI Congress of the Cretan Medical Society* 378-381, 1993
8. Hatzoglou A., Dalapascha E., Castanas E. A new method for the assay of EGF receptors in microsamples (accidification). Comparison of available techniques. *Arch. VI Congress of the Cretan Medical Society* 411-413, 1993
9. Kolyvaki S., Tampakaki M., Castanas E. Modifications and initial clinical findings of an ELISA for human Erythropoietin in serum. *Arch. VI Congress of the Cretan Medical Society* 417-419, 1993
10. Kremasmenou E., Kolyvaki S., Ampatzaki V., Kafatos A., Castanas E. Physiological variations of immunological parameters in the rural and civil population in Crete, Greece. *Arch. VI Congress of the Cretan Medical Society* 64-66, 1993
11. Nistikaki A., Hatzoglou A., Boskou D., Castanas E. Potent inhibition of human breast and prostate cancer cell lines by olive oil phenolic acids. *HSBMB Newslet.* 46, 277-281, 1999
12. Chatzaki E., Makrigiannakis A., Margioris A., Castanas E., Gravanis A. Prodynorphin-derived  $\kappa$ -opioid peptides are expressed in normal and tumoral cells of human endometrium: paracrine effects on Transforming Growth Factor beta-1. *HSBMB Newslet.* 46, 17-19, 1999
13. Kampa M., Hatzoglou A., Thermos K., Castanas E. Direct interaction of opioids with  $\alpha 1$  adrenergic receptors in the human prostate cancer cell line LNCaP. Action on cell proliferation. *HSBMB Newslet.* 46, 30-35, 1999
14. Hatzoglou A., Bakogeorgou E., Damianaki A., Tsapis A., Castanas E. Opioids promote cell proliferation in multiple myeloma cell lines by inducing IL-6 and IL-6R. *HSBMB Newsletters* 47, 221-223, 2000
15. Kampa M., Notas G., Hatzoglou A., Bakogeorgou E., Damianaki A., Kouroumalis E., Castanas E. Opioids inhibit Nitric Oxide Synthase in T47D human breast cancer cells. *HSBMB Newsletters* 47, 254-259, 2000
16. Hatzoglou A., Castanas E. Rules for the use of tumor markers in clinical practice. *Oncology Reports (Athens)* 2, 172-175, 2000

17. Koutroubakis I., Petinaki E., Anagnostopoulou E., Mouzas I.A., Castanas E., Kouroumalis E.A. Anti-saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. *Gut* 47 (Suppl II), A232, 2000

c. **Chapters, Books, Theses**

1. Castanas E., Papastratis G., Margioris A., Carydakis P., Kakaviatos N., Antypas G., Livanou Th. The influence of pharmaceutical vagotomy on serum gastrin and plasma cyclic nucleotide levels. *in* "Interdisciplinary Trends in Surgery" Minerva Medica Eds. pp 949-960, 1977
2. Castanas E. Metabolic Changes in Thalassemia. Doctoral Thesis, Athens, 1978
3. Carayon P., Castanas E., Guibout M., Codaccioni J.-L. Assessment and clinical significance of free thyroid hormone radioimmunoassays. *in*: R. Ekins, G. Faglia, F. Penisi, A. Pinchera (eds) "International Symposium on free thyroid hormones" Excerpta Medica, pp 181-205, 1979
4. Codaccioni J.L., Carayon P., Castanas E., Guibout M. Clinical interest of direct radio-immunological determination of free thyroid hormone plasma levels. *in* "Radioimmunity 1979" C.A. Bizolon (ed) Elsevier-North Holland pp 97-107, 1979
5. Castanas E. Etude longitudinale des differentes parametres de surveillance biologique apres traitement radical de la maladie de Basedow. Research Dissertation for the obtention of the speciality of Endocrinology and Metabolism. University Aix-Marseille II, 1980
6. Castanas E. Heterogeneite des formes hormonales secretees par des adenomes a prolactine. These de IIIe Cycle. Ph D Thesis, University Aix-Marseille II, 1981
7. Oliver C., Conte-Devolx B., Giraud P., Castanas E., Boudouresque F., Gunz G. Dopaminergic system and hypophyseal function. *in* "Special Aspects of Psychopharmacology" M. Ackenheil and N. Matussek (eds) Expansion Scientifique Francaise, pp 257-267, 1983
8. Castanas E. Les sites de liaison opiaces: Le modele medullosurrenallien. These d'Etat es Sciences Naturelles. Doctorate in Sciences Thesis, University Aix-Marseille II, 1985
9. Guillaume V., Dutour A., Ouafik L'H., Castanas E., Oliver C. Immunoreactive TRH and TRH-OH in rat hypophyseal portal blood. *in* "Progress in Thyroid Research" G. Madeiros-Neto and E Gaitan (eds), Plenum Press (New York & London) Vol 1, pp 295-298, 1986
10. Castanas E. Lecture Notes in Pharmacology. Heraklion, 1987
11. Castanas E. Lecture Notes in Clinical Chemistry. General Methods. Heraklion, 1988
12. Laboratory of Clinical Chemistry-Biochemistry University Hospital of Heraklion. Notes on the use of Clinical Chemistry Examinations, 1989.
13. Chinot O., Kircher C., Romain S., Castanas E., Martin P-M. Les Merqueurs tumoraux. *In* "Le praticien face au cancer du sein. Arnette-Blackwell Publ. Paris pp 163-177, 1996
14. Castanas E. Microconstituents of olive oil and their role in health. Olive tree in past and future, 1999
15. Hatzoglou A., Bakogeorgou E., Kampa M., Panagiotou S., Martin P-M., Loukas S., Castanas E. Somatostatin and Opioid Receptors in mammary tissue: Role in cancer cell growth. *Mammary Gland Biology*, Raven Press, 55-63, 1999
16. Hatzoglou A., Kampa M., Castanas E. Wine antioxidants as antiproliferative agents in hormone-dependent tumors. Minutes of the meeting of the Scientific Board of the Association "Vin et Sante", 2000
17. Kampa M, Nistikaki A, Hatzoglou A, Kouimtoglou H, Boskou D, Vercauteren J, Gravanis A, Castanas E: Phenolic acids and polyphenols are potent inhibitors of cancer cell proliferation: Assessment and mechanisms of action. *In: Polyphenols 2002: Recent advances in polyphenols research*. Edited by El-Hadrami I, Daayf F. Groupe Polyphenols; 2002: 62-93, 2002

18. Boskou D., Nistikaki A., Kampa M., Hatzoglou A., Blekas G., Castanas E. Inhibition of human breast and prostate cancer cell lines by olive oil phenolic acids. In Bahorun T., Gurib-Fakim A. (Editors) *Molecular and therapeutic aspects of redox biochemistry*. OICA International (K) Ltd London pp 239-248, 2003
19. Castanas E. Can the Mediterranean Diet be industrialized? In *"Mediterranean Diet: Past, Present and Future"* Lambrou-Philipson C, Konstantinidis K (Eds), Heliotopos Conferences, Athens, pp61-66, 2004
20. Echhouse S., Castanas E., Chieco-Bianchi L., Cinca S., Meunier F., Moulton B., Nilsson K., Ogmundsdottir HM., Ovengaard J., Vandendael K., Sullivan R. European Cancer Research Funding Survey. European Cancer Research Managers Forum QLG1-CT-2002-30203, European Commission, DG Research, 2005
21. Nifli AP, Castanas E. Polyphenols in the prevention of chronic diseases: Antioxidants and beyond. *Mediet 2005 Proceedings* (in press), 2005
22. Kampa M., Nifli A-P., Notas G., Alexaki V-I., Hatzoglou A., Castanas E. Antioxidant plant phenols and cancer cell growth. In *Antioxidant Plant Phenols: Sources, Structure-Activity Relationship, Current Trends in Analysis and Characterization*. (D. Boskou, I. Gerothanasis, P. Kefalas, Eds), Singpost Research Editions, (in press), 2006
23. Nifli AP, Kampa M, Pelekanou V, Castanas E. Wine and Health: Epidemiological-intervention evidences and new cellular mechanisms of action. *Ampelos 2006 Proceedings* 1-4, 2006
24. Charalampopoulos I, Tsatsanis C, Margioris AN, Castanas E, Gravanis A. Dehydroepiandrosterone, as endogenous inhibitor of neuronal cell apoptosis: potential therapeutic implications in neurodegenerative diseases. MS Ritsner, and A. Weizman, (editors), Springer, 2007
- 25.

### Annex 3 Patents

1. Novel small molecules derived from natural compounds for the treatment of cancer  
UK patent appl. filed Sep 2010
2. Natural anthocyanidins as anti-cancer agents  
US pat. appl. (2007) pending
3. Steroid-protein conjugates (structure, function and use of) for the treatment of cancer  
US 7,358,379, AU2003281165, US 7,495,115  
European, Canadian and Japanese applications pending
4. Steroid-protein conjugates for co-administration with erythropoietin  
European, US, Canadian, Japanese and Australian applications pending
5. ER $\alpha$  derived peptides  
Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof,  
EP10187761  
ER-alpha-17P peptide, effects on stem cell differentiation, PCT/EP2010/065557
6. Neurosteroid compounds  
C07J21/00, WO 2008155534, US 2010234335, WO 2008155534, US 2010234335, KR 20100040292, JP 2010530404, EP 2158209, EA 201070027, CN 101784558, CA 2691071, AU 2008265046
7. Treatment and prevention of inflammation  
KR 20080076856, GR1005409
8. Filtering of internal combustion oils  
GR1004835
9. Clearing of olive mills waste waters  
GR2003100295
10. Determination of Total and corrected plasma antioxidant capacity  
GR100453